GSK (GSK.US) announced today that its antibody-drug conjugate (ADC) Blenrep (belantamab mafodotin) has achieved positive results in the pre-planned interim analysis of the phase 3 clinical trial DREAMM-7.
Zhongtong Finance APP learned that GSK (GSK.US) announced today that its antibody-drug conjugate (ADC) Blenrep (belantamab mafodotin) has achieved positive results in the pre-planned interim analysis of the phase 3 clinical trial DREAMM-7. The trial evaluated the efficacy of Blenrep in combination with bortezomib and dexamethasone (BorDex) as a second or later line of treatment for relapsed or refractory multiple myeloma. The trial met the key secondary endpoint of overall survival (OS), demonstrating that Blenrep in combination with BorDex significantly reduced the risk of patient death compared to standard treatment. The results of the interim analysis, including safety data, will be presented at the upcoming 66th American Society of Hematology (ASH) annual meeting.
Blenrep is an antibody-drug conjugate targeting B-cell maturation antigen (BCMA), composed of a humanized anti-BCMA monoclonal antibody and the cytotoxic payload auristatin F linked by an uncleavable linker.
